Consensus Statements & Practice-Changing Papers
- Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update » December 2017
- Role of sentinel lymph node biopsy as a staging procedure in patients with melanoma: A critical appraisal » July 2017
- Current management of regional lymph nodes in patients with melanoma » November 2018
- Final trial report of sentinel-node biopsy versus nodal observation in melanoma » February 2014
- Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update » December 2017
- Sentinel Lymph Node Biopsy in Thick-Melanoma Patients (N=350): What is Its Prognostic Role? » June 2015
- Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. » May 2015
- Sentinel lymph node mapping in melanoma in the twenty-first century. » April 2015
- Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed? : A Single-Institution Database Study on the Prognostic Value of Tumor Mitotic Rate for Sentinel Lymph Node Status and Survival of Cutaneous Melanoma Patients. » January 2015
- Clinicopathologic predictors of survival in patients with desmoplastic melanoma. » March 2015
- Radiotherapy influences local control in patients with desmoplastic melanoma. » May 2014
- The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. » May 2014
- Desmoplastic melanoma: is there a role for sentinel lymph node biopsy? » July 2013
- Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study. » July 2015
- Lymph node dissection for stage III melanoma. » April 2015
- Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. » March 2014
- The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. » January 2014
- Is complete lymph node dissection after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? A meta-analysis. » July 2013
- Pembrolizumab versus Ipilimumab in Advanced Melanoma. » June 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. » May 2015
- Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. » May 2015
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. » April 2015
- Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. » April 2015
- The Landmark Series: Randomized Trials Examining Surgical Margins for Cutaneous Melanoma » September 2019
- Versus 2-cm Excision Margins for pT2-pT4 Primary Cutaneous Melanoma (MelMarT): A Feasibility Study » May 2018
- Long-Term Results of a prospective surgical trial comparing 2 cm vs. 4 cm Excision Margins for 740 Patients with 1-4mm Melanomas » March 2018
- Wide versus narrow excision margins for high-risk primary cutaneous melanomas: long-term follow-up of survival in a randomized trial » January 2016
- Is a wider margin (2cm vs. 1cm) for a 1.01-2.0 mm melanoma necessary? » March 2016
- Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update » December 2017
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma » June 2017
- Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node » September 2019
- Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium » July 2019
- Updates in adjuvant systemic therapy for melanoma » November 2018
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma » November 2017
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma » November 2017
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma » April 2018
- Adjuvant vemurafenib in resected, BRAF(V600) mutationpositive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial » February 2018
- Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial » January 2018
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma » August 2018
- Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial » May 2019
- Results of NCCTG N0275 (Alliance) – a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma » July 2016
- Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation » August 2019
- Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis » March 2019
- A systematic review and meta-analysis of locoregional treatments for in-transit melanoma » February 2019
- Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade » January 2019